ANL 23.10 Decreased By ▼ -0.70 (-2.94%)
ASC 16.10 Decreased By ▼ -0.30 (-1.83%)
ASL 22.25 Decreased By ▼ -0.40 (-1.77%)
BOP 8.55 Increased By ▲ 0.17 (2.03%)
BYCO 8.96 Increased By ▲ 0.15 (1.7%)
FCCL 18.07 Decreased By ▼ -0.40 (-2.17%)
FFBL 24.45 Decreased By ▼ -0.15 (-0.61%)
FFL 17.90 Decreased By ▼ -0.15 (-0.83%)
FNEL 8.40 Decreased By ▼ -0.14 (-1.64%)
GGGL 22.09 Decreased By ▼ -0.21 (-0.94%)
GGL 43.18 Decreased By ▼ -0.77 (-1.75%)
HUMNL 7.02 Decreased By ▼ -0.15 (-2.09%)
JSCL 20.85 Decreased By ▼ -0.73 (-3.38%)
KAPCO 37.90 Decreased By ▼ -0.20 (-0.52%)
KEL 3.61 Increased By ▲ 0.01 (0.28%)
MDTL 3.00 Decreased By ▼ -0.07 (-2.28%)
MLCF 36.30 Decreased By ▼ -0.18 (-0.49%)
NETSOL 153.30 Decreased By ▼ -4.45 (-2.82%)
PACE 5.98 Decreased By ▼ -0.03 (-0.5%)
PAEL 31.20 Decreased By ▼ -0.45 (-1.42%)
PIBTL 9.36 Decreased By ▼ -0.11 (-1.16%)
POWER 7.90 Decreased By ▼ -0.14 (-1.74%)
PRL 20.85 Decreased By ▼ -0.13 (-0.62%)
PTC 10.40 Increased By ▲ 0.02 (0.19%)
SILK 1.67 Decreased By ▼ -0.02 (-1.18%)
SNGP 43.19 Decreased By ▼ -0.56 (-1.28%)
TELE 22.06 Decreased By ▼ -0.64 (-2.82%)
TRG 173.50 Decreased By ▼ -2.41 (-1.37%)
UNITY 36.20 Decreased By ▼ -0.77 (-2.08%)
WTL 3.25 Decreased By ▼ -0.08 (-2.4%)
BR100 4,979 Decreased By ▼ -47.44 (-0.94%)
BR30 24,460 Decreased By ▼ -312.8 (-1.26%)
KSE100 46,636 Decreased By ▼ -284.38 (-0.61%)
KSE30 18,480 Decreased By ▼ -177.85 (-0.95%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
27,072
6824hr
Pakistan Cases
1,218,749
2,92824hr
5.08% positivity
Sindh
448,658
Punjab
419,423
Balochistan
32,707
Islamabad
103,720
KPK
170,391
World

China approves AstraZeneca's lung cancer drug

  • The drugmaker is also seeking to catch up with Swiss rival Roche, whose Tecentriq is approved in China and many other countries for extensive-stage SCLC
19 Jul 2021

China has approved AstraZeneca drug, Imfinzi, to treat an aggressive type of lung cancer in adults, the group said on Monday, in a boost to its efforts to tackle the disease.

The drug's use with chemotherapy for adult patients with extensive-stage small cell lung cancer (SCLC) was approved by China's National Medical Products Administration, the Anglo-Swedish drugmaker said.

SCLC is an aggressive form of lung cancer that typically recurs and advances despite a response to chemotherapy. Only about 3% of those with extensive-stage disease live beyond five years after diagnosis.

China's approval came after positive results from a late-stage trial, which showed that the drug, when used with chemotherapy, helped improve patients' overall survival compared to chemotherapy alone. Results from a local trial also aligned with global results, AstraZeneca said.

Germany to give different second jab to AstraZeneca recipients under 60

The drugmaker is also seeking to catch up with Swiss rival Roche, whose Tecentriq is approved in China and many other countries for extensive-stage SCLC.

AstraZeneca's lung cancer portfolio includes a range of medicines including Imfinzi, which was approved in the United States and the European Union last year for extensive-stage SCLC.

Imfinzi, which enables the immune system to detect and attack certain cancer cells, is already approved in many countries as a treatment for the more common non-small cell lung cancer.

Lung cancer accounts for roughly a fifth of all deaths from cancer and is the leading cause of cancer deaths among both men and women.

Comments

Comments are closed.